In an older patient with pembrolizumab-associated chronic eczematous dermatitis—worsened by dupilumab and with biopsies showing spongiotic dermatitis with atypical lymphocytes, would a trial of a JAK inhibitor be appropriate while monitoring for possible early CTCL?